Literature DB >> 25677906

The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma.

Bin Zhang1, Bin Song, Xin Wang, Xu-Sheng Chang, Tao Pang, Xin Zhang, Kai Yin, Guo-En Fang.   

Abstract

The ectonucleotidase CD73 degrades adenosine triphosphate (ATP) to adenosine which potently inhibits host immune responses against cancer. This study investigated the expression level and prognostic significance of CD73 in human rectal adenocarcinoma. Our data demonstrated that CD73 staining strongly marked both malignant epithelial cells and stromal components where the protein and messenger RNA (mRNA) expression levels of CD73 were significantly increased compared with paracancerous controls. High CD73 expression in tumor cells can be used as an independent factor for predicting poor patients' prognosis; however, patients with higher density of stromal CD73 were more likely to have favorable characteristics (early T and tumor-node-metastasis (TNM) stages) and overall survival. Notably, combined CD73 expression analysis in both tumoral and stromal compartments was more efficient to foretell patient's outcome where patients with increased CD73 in tumor cells but decreased CD73 in stroma displayed a worst prognosis. Taken together, the current study revealed CD73 expression was increased in both tumoral and stromal compartments. Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25677906     DOI: 10.1007/s13277-015-3212-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  High expression of CD73 as a poor prognostic biomarker in human colorectal cancer.

Authors:  Xian-Rui Wu; Xiao-Sheng He; Yu-Feng Chen; Rui-Xue Yuan; Yang Zeng; Lei Lian; Yi-Feng Zou; Nan Lan; Xiao-Jian Wu; Ping Lan
Journal:  J Surg Oncol       Date:  2012-01-27       Impact factor: 3.454

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

3.  Activities of adenosine deaminase and 5'-nucleotidase in cancerous and noncancerous human colorectal tissues.

Authors:  A Eroglu; O Canbolat; S Demirci; H Kocaoglu; Y Eryavuz; H Akgül
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

4.  Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.

Authors:  Mikkel G Terp; Kristina A Olesen; Eva C Arnspang; Rikke R Lund; B Christoffer Lagerholm; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

5.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

6.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Authors:  Paul A Beavis; Upulie Divisekera; Christophe Paget; Melvyn T Chow; Liza B John; Christel Devaud; Karen Dwyer; John Stagg; Mark J Smyth; Phillip K Darcy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-20       Impact factor: 11.205

7.  Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Authors:  Bertrand Allard; Sandra Pommey; Mark J Smyth; John Stagg
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

8.  Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

Authors:  Maria T Diaz-Meco; Jorge Moscat; Tania Valencia; Ji Young Kim; Shadi Abu-Baker; Jorge Moscat-Pardos; Christopher S Ahn; Miguel Reina-Campos; Angeles Duran; Elias A Castilla; Christian M Metallo
Journal:  Cancer Cell       Date:  2014-07-04       Impact factor: 31.743

Review 9.  Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis.

Authors:  Massimo Pancione; Guido Giordano; Andrea Remo; Antonio Febbraro; Lina Sabatino; Erminia Manfrin; Michele Ceccarelli; Vittorio Colantuoni
Journal:  J Immunol Res       Date:  2014-01-16       Impact factor: 4.818

10.  Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling.

Authors:  Stefano Maria Pagnotta; Carmelo Laudanna; Massimo Pancione; Lina Sabatino; Carolina Votino; Andrea Remo; Luigi Cerulo; Pietro Zoppoli; Erminia Manfrin; Vittorio Colantuoni; Michele Ceccarelli
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more
  21 in total

1.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

Review 2.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

3.  High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.

Authors:  Bin Zhang; Bo Cheng; Feng-Sheng Li; Jian-Hua Ding; Ying-Ying Feng; Guang-Zuan Zhuo; Hua-Feng Wei; Ke Zhao
Journal:  Tumour Biol       Date:  2015-06-27

4.  CD73s protection of epithelial integrity: Thinking beyond the barrier.

Authors:  Jessica L Bowser; Russell R Broaddus
Journal:  Tissue Barriers       Date:  2016-08-19

5.  Identification of mRNA Signature for Predicting Prognosis Risk of Rectal Adenocarcinoma.

Authors:  Linlin Jiang; Peng Wang; Mu Su; Lili Yang; Qingbo Wang
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

6.  NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia.

Authors:  Vitória Brum da Silva Nunes; Camila Kehl Dias; Marco Antônio De Bastiani; Mariela Granero Farias; Fabiane Spagnol; Ana Paula Alegretti; Liane Esteves Daudt; Mariana Bohns Michalowski; Ana Maria Oliveira Battastini; Alessandra Aparecida Paz; Fabrício Figueiró
Journal:  Purinergic Signal       Date:  2022-03-02       Impact factor: 3.950

7.  The role of extracellular-5'-nucleotidase/CD73 in glioma peritumoural brain edema.

Authors:  Bo Wang; Dong Wang; ZhiZhong Zhu; Wei Wang; XueBin Zhang; Fan Tang; Yu Zhou; HongGuang Wang; MengYuan Liu; Xin Yao; XiaoLing Yan
Journal:  Neurol Sci       Date:  2016-02-16       Impact factor: 3.307

Review 8.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

9.  Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.

Authors:  Jun Zhao; Luisa M Solis Soto; Hua Wang; Matthew H Katz; Laura R Prakash; Michael Kim; Ching-Wei D Tzeng; Jeffrey E Lee; Robert A Wolff; Yanqing Huang; Ignacio I Wistuba; Anirban Maitra; Huamin Wang
Journal:  Pancreatology       Date:  2021-04-01       Impact factor: 3.996

Review 10.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Authors:  Robert D Leone; Ying-Chun Lo; Jonathan D Powell
Journal:  Comput Struct Biotechnol J       Date:  2015-04-08       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.